Search company, investor...

Habitu

habitu.health

Founded Year

2018

Stage

Acquired | Acquired

About Habitu

Habitu offers an AI-based solution for Adaptive Trial Management aiming to create burdenless, positive experiences across life-routines and points-of-care for more efficient clinical trial performance.On January 11th, 2021, Habitu was acquired by RxE2. The terms of the transaction were not disclosed.

Headquarters Location

Herzliya,

Israel

Missing: Habitu's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Habitu's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Habitu

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Habitu is included in 1 Expert Collection, including Digital Health.

D

Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest Habitu News

RxE2 Agrees to Acquire Habitu to Form the First AI Driven, Pharmacist-Led, Clinical Trial Platform

Jan 12, 2021

Share New Approach Will Combine Pharmacist Services With Advanced Technology and AI to Create a Fundamental Change in the Way Traditional and Decentralized Clinical Trials Are Conducted. RxE2, which is bringing the practice of pharmacy to clinical research, announced it has agreed to acquire Habitu, an Israeli-based technology company. Habitu focuses on people’s habits and behaviors to create a KyP engine enabled by artificial intelligence, improving patient outcomes by providing real-time analyses of a more comprehensive set of patient data. The engine is built on top of a distributed clinical trials management platform. Habitu’s technology, using its AI powered efficiency tools, will greatly enhance RxE2’s pharmacist-led trial services and allow cost-effective scalability. Credit RxE2 “To date, the responsibility has been on the patient to conform to the requirements of a clinical trial for the purpose of collecting data, including traveling long distances to the clinical site, spending long hours at the site, and working with unfamiliar healthcare professionals. Conversely, our approach is to adapt the clinical trial to fit the patient’s daily routine, leveraging the traditional, trusted pharmacist-patient relationship to go beyond data collection. We gather real-world patient information, and thus gain knowledge,” said  Gerald Finken, CEO of RxE2. “This approach enables the continuous collection not only of clinical data but also of the crucial subjective, emotional, and behavioral data, which puts the clinical data into context. This contextual information has previously gone unrecorded by clinical sites and we have proven that it is central to the success of any study. The Habitu KyP engine and AI provides pharmacists with a unique tool to better serve their patients and provide quality data for clinical research.” Related Posts Habitu’s technology platform enables RxE2 to provide and manage pharmacist-led trial services in a distributed model which localizes the decentralized clinical trial model. Pharmacists can quickly onboard to the platform and instantly identify appropriate clinical trials for their patients. In addition, Habitu’s technology platform will provide all RxE2 pharmacies with a single integrated system for collecting both clinical and subjective data. Based on input from pharmacists, behavior patterns of patients, machine learning, and predictive algorithms, Habitu’s AI can foresee and predict potential challenges. Sharing identified issues with pharmacists and medical teams allows them to make better decisions, proactively avert crises, and improve patient outcomes. Yaniv Zilberman , COO of RxE2 and former CEO of Habitu said, “This is a new way of using advanced technology to solve today’s clinical trial challenges and on a grand scale. Gerald Finken’s vision to improve clinical drug trials by leveraging the trusted, local pharmacist-patient relationship combined with Habitu’s advanced technology and AI platform is certain to dramatically improve clinical trial outcomes, make clinical trials patient-centric, and improve clinical results from every aspect.”

Habitu Frequently Asked Questions (FAQ)

  • When was Habitu founded?

    Habitu was founded in 2018.

  • Where is Habitu's headquarters?

    Habitu's headquarters is located at Herzliya.

  • What is Habitu's latest funding round?

    Habitu's latest funding round is Acquired.

  • Who are the investors of Habitu?

    Investors of Habitu include RxE2.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.